Completed PHASE2 INTERVENTIONAL NCT00107003

GW572016 to Treat Recurrent Malignant Brain Tumors

A Biomarker and Phase II Study of GW572016 in Recurrent Malignant Glioma

Sponsor: National Cancer Institute (NCI)

Conditions Brain Tumor GBM GS Glioblastoma Multiforme Glioma Gliosarcoma

Interventions Adjuvant therapy Conventional surgery Neoadjuvant therapy lapatinib ditosylate

Updated 7 times since 2017 Last updated: Jul 3, 2018 Started: Mar 30, 2005 Primary completion: Dec 5, 2007 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00107003, this PHASE2 trial focuses on Brain Tumor and GBM and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States